Return to Intended Oncologic Treatment (RIOT): A Novel Metric for Evaluating the Quality of Oncosurgical Therapy for Malignancy

被引:143
作者
Aloia, Thomas A. [1 ]
Zimmitti, Giuseppe [1 ]
Conrad, Claudius [1 ]
Gottumukalla, Vijaya [2 ]
Kopetz, Scott [3 ]
Vauthey, Jean-Nicolas [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Anesthesia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
基金
美国国家卫生研究院;
关键词
surgical oncology; adjuvant therapy; colorectal liver metastases; minimally invasive surgery; outcomes; COLORECTAL LIVER METASTASES; ADJUVANT CHEMOTHERAPY; HEPATIC RESECTION; SURGICAL RESECTION; DOSE INTENSITY; BREAST-CANCER; PHASE-III; SURVIVAL; SURGERY; RECURRENCE;
D O I
10.1002/jso.23626
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: After cancer surgery, complications, and disability prevent some patients from receiving subsequent treatments. Given that an inability to complete all intended cancer therapies might negate the oncologic benefits of surgical therapy, strategies to improve return to intended oncologic treatment (RIOT), including minimally invasive surgery (MIS), are being investigated. Methods: This project was designed to evaluate liver tumor patients to determine the RIOT rate, risk factors for inability to RIOT, and its impact on survivals. Outcomes for a homogenous cohort of 223 patients who underwent open-approach surgery for metachronous colorectal liver metastases and a group of 27 liver tumor patients treated with MIS hepatectomy were examined. Results: Of the 223 open-approach patients, 167 were offered postoperative therapy, yielding a RIOT rate of 75%. The remaining 56 (25%) patients were unable to receive further treatment due to surgical complications (n = 29 pts) or poor performance status (n = 27 pts). Risk factors associated with inability to RIOT were hypertension (OR 2.2, P = 0.025), multiple preoperative chemotherapy regimens (OR 5.9, P = 0.039), and postoperative complications (OR 2.0, P = 0.039). Inability to RIOT correlated with shorter disease-free and overall survivals (P < 0.001, HR = 2.16; and P = 0.005, HR 2.07, respectively). In contrast to the open surgery group, 100% of MIS patients who were intended to initiate postoperative therapy did so (P 0.038) within a shorter median time interval (MIS: 15 days vs. open: 42 days; P < 0.001). Conclusions: The relationship between RIOT and long-term oncologic outcomes suggests that RIOT rates for both open-and MIS-approach cancer surgery should routinely be reported as a quality indicator. (C) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:107 / 114
页数:8
相关论文
共 38 条
[21]   Resected Colorectal Liver Metastases: Does the Survival Differ According to Postoperative Chemotherapy Regimen? [J].
Kim, Sun Young ;
Kim, Hee Jun ;
Hong, Yong Sang ;
Jung, Kyung Hae ;
Park, Ji Won ;
Choi, Hyo Seong ;
Oh, Jae Hwan ;
Park, Sang-Jae ;
Kim, Seong Hoon ;
Nam, Byung-Ho ;
Chang, Hee Jin ;
Kim, Dae Yong .
JOURNAL OF SURGICAL ONCOLOGY, 2009, 100 (08) :713-718
[22]   Perioperative chemotherapy for resectable hepatic metastases [J].
Kopetz, Scott ;
Vauthey, Jean-Nicolas .
LANCET, 2008, 371 (9617) :963-965
[23]   Improved Survival in Metastatic Colorectal Cancer Is Associated With Adoption of Hepatic Resection and Improved Chemotherapy [J].
Kopetz, Scott ;
Chang, George J. ;
Overman, Michael J. ;
Eng, Cathy ;
Sargent, Daniel J. ;
Larson, David W. ;
Grothey, Axel ;
Vauthey, Jean-Nicolas ;
Nagorney, David M. ;
McWilliams, Robert R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) :3677-3683
[24]   PROGNOSTIC-SIGNIFICANCE OF ACTUAL DOSE INTENSITY IN DIFFUSE LARGE-CELL LYMPHOMA - RESULTS OF A TREE-STRUCTURED SURVIVAL ANALYSIS [J].
KWAK, LW ;
HALPERN, J ;
OLSHEN, RA ;
HORNING, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (06) :963-977
[25]   Transhepatic ipsilateral right portal vein embolization extended to segment IV: Improving hypertrophy and resection outcomes with spherical particles and coils [J].
Madoff, DC ;
Abdalla, EK ;
Gupta, S ;
Wu, TT ;
Morris, JS ;
Denys, A ;
Wallace, MJ ;
Morello, FA ;
Ahrar, K ;
Murthy, R ;
Lunagomez, S ;
Hicks, ME ;
Vauthey, JN .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2005, 16 (02) :215-225
[26]  
Merkow RP., 2013, Ann Surg
[27]   Adjuvant Chemotherapy After Potentially Curative Resection of Metastases From Colorectal Cancer: A Pooled Analysis of Two Randomized Trials [J].
Mitry, Emmanuel ;
Fields, Anthony L. A. ;
Bleiberg, Harry ;
Labianca, Roberto ;
Portier, Guillaume ;
Tu, Dongsheng ;
Nitti, Donato ;
Torri, Valter ;
Elias, Dominique ;
O'Callaghan, Chris ;
Langer, Bernard ;
Martignoni, Giancarlo ;
Bouche, Olivier ;
Lazorthes, Franck ;
Van Cutsem, Eric ;
Bedenne, Laurent ;
Moore, Malcolm J. ;
Rougier, Philippe .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) :4906-4911
[28]  
Nakajima Y, 2001, HEPATO-GASTROENTEROL, V48, P1680
[29]   CLINICAL-TRIAL OF ADJUVANT CHEMOTHERAPY AFTER SURGICAL RESECTION OF COLORECTAL-CANCER METASTATIC TO THE LIVER [J].
OCONNELL, MJ ;
ADSON, MA ;
SCHUTT, AJ ;
RUBIN, J ;
MOERTEL, CG ;
ILSTRUP, DM .
MAYO CLINIC PROCEEDINGS, 1985, 60 (08) :517-520
[30]   Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents [J].
Parks, Rowan ;
Gonen, Mithat ;
Kemeny, Nancy ;
Jarnagin, William ;
D'Angelica, Michael ;
DeMatteo, Ronald ;
Garden, O. James ;
Blumgart, Leslie H. ;
Fong, Yuman .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2007, 204 (05) :753-761